Navigation Links
Despite Patent Expiries of Leading Therapies, New Product Launches Will Drive a $4.6 Billion Increase in the Coronary Heart Disease Market
Date:3/24/2009

Growth Will be Driven by Drugs from Eli Lilly/Daiichi Sankyo, AstraZeneca, and Schering-Plough, According to a New Report from Decision Resources

WALTHAM, Mass., March 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the patent expiries by 2012 of the two sales-leading therapies, new product launches will drive an increase of $4.6 billion in the overall coronary heart disease market by 2017.

The new Pharmacor report entitled Coronary Heart Disease finds that the market to treat the disease will grow from $14.8 billion in 2007 to $19.4 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Growth will be driven by the launches of Eli Lilly/Daiichi Sankyo's Efient/Effient, AstraZeneca's Brilinta and Schering-Plough's SCH-530348 as well as the introduction of two new CETP inhibitors from Roche/Japan Tobacco and Merck.

Despite the patent expiry of the two sales-leading coronary heart disease therapies by 2012 -- Sanofi-Aventis/Bristol-Myers Squibb's Plavix/Iscover and Pfizer's Lipitor -- the market entry of fixed-dose combinations with agents such as Abbott's Tricor/TriLipix, Solvay's Lipanthyl and Abbott's Niaspan will also offset the negative impact of generic erosion, according to the report.

"Cardiologists' approach to coronary heart disease therapy has experienced a remarkable international convergence as optimal drug treatment for post-myocardial infarction -- the condition that accounts for more than 70 percent of coronary heart disease market sales -- now consists of two antiplatelet agents, including aspirin, a statin, an ACE inhibitor and a beta blocker," said Decision Resources Therapeutic Area Director Nikhil Mehta. "Multidrug therapy has also become routine in the treatment of stable angina. The arrival of novel agents will be welcomed by clinicians, particularly for high-risk patients, but some of these therapies could face market access and compliance hurdles."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                         Decision Resources, Inc.
    Christopher Comfort                        Elizabeth Marshall
    781-296-2597                               781-296-2563
    ccomfort@dresources.com                    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hagerstown Cosmetic Surgeon Weathers the Current Economic Storm Despite the Sharp Decline in the Number of Cosmetic Surgeries Performed Nationwide
2. The Center for Plastic Surgery in Washington, DC Survives the Economy Despite Nationwide Data Reported by ASAPS
3. Life Sciences Quality Managers Seek to Expand Compliance Initiatives Despite Economic Pressures
4. Georgia Metal Finisher Expands Despite Struggling Economy
5. Sexual health promotion is low among people with serious mental illnesses, despite higher risk
6. Code Pink Boot Camp Thrives Despite Rough Economy
7. State Health Reforms Progress Despite Ailing Economy
8. OrthoSynetics(TM) Same Practice New Contracts and Consults Growing Despite Economic Downturn
9. Americans Continue Eating Nutritious and Convenient Snacks Despite Tough Economic Times
10. Photos: Despite Widespread Awareness, Most Women Still Dont Feel at Risk for Cervical Cancer
11. Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
Breaking Medicine Technology: